American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial ...

Industry veteran brings expertise to scale patient access to life-changing individualized therapies Hugh Hempel with Twin ...

VANCOUVER, BC / ACCESSWIRE / October 3, 2024 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTC Pink:TGIFF), a Nevada-focused cannabis cultivator and producer, announces that ...

MURFREESBORO, TN / ACCESSWIRE / October 3, 2024 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the third quarter ended September 30, 2024. NHI plans ...

Opportunities for Collaboration Continue to Draw Independent Large and Small Practices From Across the CountryPUYALLUP, WA / ACCESSWIRE / October 3, 2024 / The newly established ONCare Alliance, which ...

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors Enara Bio’s EDAPT® ...

IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for ...

A Delicious, Soy-Free Blend Supporting Muscle Growth, Recovery, and Overall WellnessOCALA, FL / ACCESSWIRE / October 3, 2024 ...

LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring ...

This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people ...

Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life ...

Syncona’s £63.5 million Series B commitment will be used by Resolution to progress the company and advance its lead candidate, RTX001 in end-stage liver diseaseRTX001 is expected to enter the clinic ...